TDM-1 Heavy Hitter in Heavily Treated Breast Cancer

Joseph Gligorov, MD, PhD; Javier Cortés, MD, PhD


October 07, 2013

This feature requires the newest version of Flash. You can download it here.
In This Article


Joseph Gligorov, MD, PhD: Hello. I am Joseph Gligorov, medical oncologist at Tenon Hospital, part of the Cancer University Institute, Université Pierre et Marie Curie, Sorbonne University, Paris, France. Welcome to this edition of Medscape Oncology Insights on breast cancer, coming to you from the 2013 European Cancer Congress in Amsterdam. Joining me today is Professor Javier Cortés, Head of the Breast Cancer Program at Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, in Barcelona, Spain. Welcome, Javier.

Javier Cortés, MD, PhD: Thanks so much, Joseph.

TH3RESA and Biomarkers Get Top Billing

Dr. Gligorov: We will have a lot of information at this meeting, but let's begin with a particular population that we work with every day: the HER2-positive breast cancers. What do you consider the most significant findings from this year's Congress?

Dr. Cortés: This is a great time for HER2-positive metastatic breast cancer patients because they are living longer and better. It is difficult to highlight the most important data we have from this meeting. If I had to summarize the meeting in 2 or 3 key points, I would mention the presentation of the TH3RESA trial[1] and the analysis of the biomarkers from the BOLERO-3 clinical trial,[2] which was presented this year at the American Society of Clinical Oncology (ASCO®).[3] I would say that these 2 presentations are the most important ones at this meeting.

Dr. Gligorov: Let's begin with the TH3RESA trial. We have had some very important results from the EMELIA trial[4] showing that in the second line, comparing TDM-1 with the capecitabine-lapatinib combination, TDM-1 was found superior with respect to overall survival and progression-free survival. Could you review the design of the TH3RESA trial and then go through the results?


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: